A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Cross-Over Study To Examine The Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Aug 2013
Price : $35 *
At a glance
- Drugs PF 6305591 (Primary)
- Indications Pain
- Focus Pharmacodynamics
- 08 Jul 2013 Planned End Date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2013 Planned End Date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.